Literature DB >> 19010560

Phase I-II studies on accelerated IMRT in breast carcinoma: technical comparison and acute toxicity in 332 patients.

Alessio G Morganti1, Savino Cilla, Vincenzo Valentini, Cinzia Digesu', Gabriella Macchia, Francesco Deodato, Gabriella Ferrandina, M Grazia Cece, Massimo Cirocco, Giorgia Garganese, Liberato Di Lullo, Divina Traficante, Francesca Scarabeo, Simona Panunzi, Andrea De Gaetano, Giuseppina Sallustio, Numa Cellini, Luigi Sofo, Angelo Piermattei, Giovanni Scambia.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate the results in terms of dosimetric parameters and acute toxicity of two clinical studies (MARA-1 and MARA-2) on accelerated IMRT-based postoperative radiotherapy. These results are compared with historical control group (CG) of patients treated with "standard" 3D postoperative radiotherapy.
MATERIALS AND METHODS: Prescribed dose to the breast was 50.4Gy in the CG, 40Gy in MARA-1 (low risk of local recurrence), and 50Gy in MARA-2 (medium-high risk of recurrence). The tumor bed total dose was 60.4Gy (sequential 10Gy electron boost), 44Gy (concomitant 4Gy boost), and 60Gy (concomitant 10Gy boost) in CG, MARA-1 and MARA-2 studies, respectively. Overall treatment time was of 32 fractions for CG (6.4weeks); 16 fractions for MARA-1 study (3.2weeks) and 25 fractions for MARA-2 study (5weeks).
RESULTS: Three hundred and thirty two patients were included in the analysis. Dosimetric analysis showed D(max) and V(107%) reduction (p<0.001) and D(min) improvement (p<0.001) in the PTV in patients treated with IMRT. Grade 2 acute skin toxicity was 33.6%, 13.1%, and 45.1% in the CG, MARA-1, and MARA-2, respectively (p<0.001), and grade 3 acute skin toxicity was 3.1%, 1.0%, and 2.0%, respectively. Similarly, larger PTV and use of chemotherapy with anthracyclines and taxanes were associated with a greater acute toxicity. With a median follow-up of 31 months, no patients showed local or nodal relapse.
CONCLUSIONS: A simplified step and shoot IMRT technique allowed better PTV coverage and reduced overall treatment time (CG, 6.6weeks; MARA-1, 3.2weeks; MARA-2, 5weeks) with acceptable short-term toxicity.

Entities:  

Mesh:

Year:  2008        PMID: 19010560     DOI: 10.1016/j.radonc.2008.10.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

1.  Comparison between intensity modulated radiotherapy (IMRT) and 3D tangential beams technique used in patients with early-stage breast cancer who received breast-conserving therapy.

Authors:  Beata Sas-Korczyńska; Anna Sladowska; Bożena Rozwadowska-Bogusz; Sonia Dyczek; Jan Lesiak; Anna Kokoszka; Stanisław Korzeniowski
Journal:  Rep Pract Oncol Radiother       Date:  2010-08-04

Review 2.  Hypofractionated breast irradiation: a multidisciplinary review of the Senonetwork study group.

Authors:  Bruno Meduri; Fiorenza De Rose; Carlo Cabula; Isabella Castellano; Lucia Da Ros; Massimo Maria Grassi; Sandra Orrù; Fabio Puglisi; Rubina Manuela Trimboli; Antonella Ciabattoni
Journal:  Med Oncol       Date:  2021-05-10       Impact factor: 3.064

Review 3.  Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence.

Authors:  Pierfrancesco Franco; Domenico Cante; Piera Sciacero; Giuseppe Girelli; Maria Rosa La Porta; Umberto Ricardi
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

4.  Hypofractionated radiotherapy with concomitant boost for breast cancer: a dose escalation study.

Authors:  Edy Ippolito; Carla Germana Rinaldi; Sonia Silipigni; Carlo Greco; Michele Fiore; Antonella Sicilia; Lucio Trodella; Rolando Maria D'Angelillo; Sara Ramella
Journal:  Br J Radiol       Date:  2018-11-28       Impact factor: 3.039

Review 5.  Current role of modern radiotherapy techniques in the management of breast cancer.

Authors:  Gokhan Ozyigit; Melis Gultekin
Journal:  World J Clin Oncol       Date:  2014-08-10

6.  Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities.

Authors:  Alba Fiorentino; Fabiana Gregucci; Rosario Mazzola; Vanessa Figlia; Francesco Ricchetti; Gianluisa Sicignano; Niccolo Giajlevra; Ruggero Ruggieri; Sergio Fersino; Stefania Naccarato; Alberto Massocco; Stefanie Corradini; Filippo Alongi
Journal:  Radiol Med       Date:  2018-12-13       Impact factor: 3.469

7.  Predictive factors of radiation-induced skin toxicity in breast cancer patients.

Authors:  Miao-Fen Chen; Wen-Cheng Chen; Chia-Hsuan Lai; Chao-Hsiung Hung; Kuo-Chi Liu; Yin-Hsuan Cheng
Journal:  BMC Cancer       Date:  2010-09-23       Impact factor: 4.430

8.  Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities.

Authors:  Grazia Tortorelli; Luana Di Murro; Rosaria Barbarino; Sara Cicchetti; Daniela di Cristino; Maria Daniela Falco; Dahlia Fedele; Gianluca Ingrosso; Dania Janniello; Pasquale Morelli; Alessandra Murgia; Elisabetta Ponti; Sara Terenzi; Barbara Tolu; Riccardo Santoni
Journal:  BMC Cancer       Date:  2013-05-07       Impact factor: 4.430

9.  Tangential beam IMRT versus tangential beam 3D-CRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison.

Authors:  Volker Rudat; Abdul Aziz Alaradi; Adel Mohamed; Khaled Ai-Yahya; Saleh Altuwaijri
Journal:  Radiat Oncol       Date:  2011-03-21       Impact factor: 3.481

10.  Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor®).

Authors:  Rossella Di Franco; MariaGrazia Calvanese; Paola Murino; Roberto Manzo; Cesare Guida; Davide Di Gennaro; Caterina Anania; Vincenzo Ravo
Journal:  Radiat Oncol       Date:  2012-01-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.